z-logo
open-access-imgOpen Access
Serotype Distribution of Clinical Streptococcus pneumoniae Isolates before the Introduction of the 13-Valent Pneumococcal Conjugate Vaccine in Cambodia
Author(s) -
Malin Inghammar,
Youlet By,
Christina M. Farris,
Thong Phe,
Laurence Borand,
Alexandra Kerléguer,
Sophie Goyet,
Vonthanak Saphonn,
Chanleakhena Phoeung,
Sirenda Vong,
Blandine Rammaert,
Charles Mayaud,
Bertrand Guillard,
Chadwick Y. Yasuda,
Matthew R. Kasper,
Gavin W. Ford,
Steven W. Newell,
Ung Sam An,
Buth Sokhal,
Sok Touch,
Paul Turner,
Jan Jacobs,
Mélina Messaoudi,
Florence Komurian-Pradel,
Arnaud Tarantola
Publication year - 2018
Publication title -
american journal of tropical medicine and hygiene
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.015
H-Index - 151
eISSN - 1476-1645
pISSN - 0002-9637
DOI - 10.4269/ajtmh.17-0692
Subject(s) - streptococcus pneumoniae , serotype , pneumococcal conjugate vaccine , microbiology and biotechnology , pneumococcal infections , conjugate vaccine , vaccination , virology , pneumococcal disease , medicine , biology , antibiotics
Childhood vaccination with the 13-valent pneumococcal conjugate vaccine (PCV13) was introduced in Cambodia in January 2015. Baseline data regarding circulating serotypes are scarce. All microbiology laboratories in Cambodia were contacted for identification of stored isolates of Streptococcus pneumoniae from clinical specimens taken before the introduction of PCV13. Available isolates were serotyped using a multiplex polymerase chain reaction method. Among 166 identified isolates available for serotyping from patients with pneumococcal disease, 4% were isolated from upper respiratory samples and 80% were from lower respiratory samples, and 16% were invasive isolates. PCV13 serotypes accounted for 60% (95% confidence interval [CI] 52-67) of all isolates; 56% (95% CI 48-64) of noninvasive and 77% (95% CI 57-89) of invasive isolates. Antibiotic resistance was more common among PCV13 serotypes. This study of clinical S. pneumoniae isolates supports the potential for high reduction in pneumococcal disease burden and may serve as baseline data for future monitoring of S. pneumoniae serotypes circulation after implementation of PCV13 childhood vaccination in Cambodia.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom